ACHE and myasthenia gravis: Among individuals in the MG group, 59% were on chronic immunosuppressive therapies (55% on prednisone, 9% on azathioprine, and 11% on mycophenolate), 37% on symptomatic treatment (acetylcholinesterase inhibition and pyridostigmine), and 8% were recently treated with IVIG within 6 months before the COVID-19 diagnosis.